Skip to main content
. 2019 Jul 19;3(14):2199–2204. doi: 10.1182/bloodadvances.2019000445

Figure 1.

Figure 1.

Late relapse study design and driver mutation analysis. (A) Time to relapse (in years) after alloHCT for AML, myelodysplastic syndrome (MDS), or myeloproliferative disease between 2001 and 2015 at our institution. (B) Schematic of trio targeted sequencing and microarray analysis for 25 patients. (C) Scatter plot showing variant allele frequency (VAF) at time of paired pretransplantation and relapse samples. (D) Alterations in myeloid driver mutations at relapse. Mutations were categorized as lost if they were present at ≥0.02 VAF pretransplantation and absent or <0.02 VAF at relapse. Similarly, mutations were categorized as gained if they were absent or <0.02 VAF pretransplantation and present at ≥0.02 VAF at relapse. CGH, comparative genome hybridization.